As the world marks the International Childhood Cancer Day (ICCD) today, childhood cancer survivors, families, and experts have called on the federal ...
Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
Everyday Health on MSN1d
4 Ways Polycythemia Vera Can Affect Your Quality of Life — and What You Can Do About ItJust like any chronic health condition, polycythemia vera (PV) can have a negative impact on your everyday life. Research has ...
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with ...
These drugs, discovered decades ago, continue to save lives today, but more recent research has led to the development of ...
Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...
NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback